The effects of simultaneous intravenous infusions of 12 mg recombinant tissue-type plasminogen activator (rt-PA) over 30 minutes and 48 mg single-chain urokinase-type plasminogen activator (scuPA) over 40 minutes were studied in 38 patients with acute myocardial infarction. Coronary arterial patency was assessed angiographically 60 minutes and 90 minutes after initiation of treatment. Patency was achieved in 19 of 31 patients (61.3%) (95% confidence limits, 42-78%) at 60 minutes and in 27 of 33 patients (81.8%) (95% confidence limits, 65-93%) at 90 minutes. Nonspecific plasminogen activation was monitored by measuring relevant plasma parameters. At 60 minutes and 120 minutes, the fibrinogen concentration decreased slightly to 82.8±24.3% and 91.2±17.4% of the preinfusion level, and the plasminogen concentration to 66.3+± 15.2% and 65.3+13.4%, respectively. A greater consumption of ,2-antiplasmin was observed, which decreased to 30.7+22.8% and 32.2+±21.2% of the preinfusion level at 60 and 120 minutes, respectively. No bleeding necessitating transfusion was observed. Two patients (5.3%) died during hospitalization. The findings suggest that the combined intravenous infusion of rt-PA and scuPA at appropriate doses induces highly effective coronary thrombolysis equal to the best results obtained with either rt-PA or scuPA alone. This efficacy is coupled with high specificity. Thus, the data support the potential use of combinations of rt-PA and scuPA in place of monotherapy. (Circulation 1990;81:907-913 possible with certain combinations of rt-PA and scuPA to induce more effective thrombolysis without compromising specificity. By lowering the overall dose requirements, it might be additionally possible to reduce the cost of therapy.
C oronary angiographic studies indicate that most Q wave acute myocardial infarctions are caused by coronary thrombosis.' Intravenous thrombolytic therapy by several plasminogen activators is capable of inducing early coronary reperfusion, thereby preserving left ventricular function2'3 and reducing both mortality and morbidity.4-7 Streptokinase and urokinase are nonspecific plasminogen activators that induce systemic plasmin possible with certain combinations of rt-PA and scuPA to induce more effective thrombolysis without compromising specificity. By lowering the overall dose requirements, it might be additionally possible to reduce the cost of therapy.
The present study was designed to evaluate this concept. A dosage combination was chosen that was estimated to be just below the threshold at which fibrinogen degradation would be anticipated.
Methods

Material
Human scuPA was highly purified from the conditioned medium of the transformed kidney cellline TCL-598. The material was made available by Sandoz AG, Nurnberg, FRG. The drug was supplied in vials containing 3.75 mg freeze-dried scuPA and human serum albumin as a stabilizer. It was stored at 40 C and dissolved in water immediately before use. The purified, glycosylated protein had a latent specific activity of about 130,000 IU/mg as measured with the chromogenic substrate S-2444 (Kabi Diagnostica) after activation with plasmin. There was virtually no measurable urokinase activity (<1%) in the purified preparation. Recombinant tissue-type plasminogen activator was purchased from Thomae GmbH, Biberach, FRG. The drug was handled according to the manufacturer's instructions. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) it proved to be predominantly single-chain material. Both drugs were infused with constant rate infusion pumps through separate infusion lines.
Patients
Inclusion criteria consisted of chest pain typical of myocardial infarction lasting for more than 30 minutes, diagnostic electrocardiographic ST segment elevation of 2 mm in at least three leads or 1 mm in at least three leads accompanied by ST segment depression in three corresponding leads, presentation within 6 hours after the onset of pain, age less than 75 years, and informed consent.
Exclusion criteria were recent (<3 months) trauma, stroke or major surgery, previous myocardial damage in the infarct territory, cardiopulmonary resuscitation, cardiogenic shock (systolic blood pressure, <80 mm Hg), hypertension (systolic blood pressure, >200 mmHg; diastolic blood pressure, >110 mmHg; or both) unresponsive to therapy within 10 minutes, or evidence of recent or active bleeding (e.g., peptic ulcer and hemoptysis). The study protocol had been approved by the institutional ethics committee.
Treatment
Patients were anticoagulated with 5,000 units heparin at the start of treatment and 7,500 units just before cardiac catheterization (at 45 minutes). A bolus of 3.7 mg scuPAwas applied over 1 All patients were followed during the time of hospitalization. Intravenous heparin was given at a dose designed to prolong the partial thromboplastin time two to threefold for at least 3 days.
Immediately after the cardiac catheterization procedure, aspirin (325-500 mg/day) was given. Patients received intravenous ,8-blockers and nitroglycerin unless contraindicated.
Repeat cardiac catheterization was performed at 21 days to determine late patency of the infarctrelated vessel although this was not considered a study end point. Angioplasty of the infarct-related artery was performed during repeat catheterization in cases with high-grade residual stenosis, an exercise thallium-scan positive for ischemia, or both.
Coagulation Parameters
Blood samples were obtained from 34 patients before initiation of thrombolytic therapy and 60 and 120 minutes after the start of therapy. Blood was collected on citrate (final concentration, 0.01 M) and immediately centrifuged at 4°C. Serum was quickfrozen and stored at -80°C. Fibrinogen,27 plasminogen,28 and a2-antiplasmin29 levels were determined from frozen samples.
Severe bleeding was defined as either a blood loss resulting in the necessity of transfusions, or a decline in hemoglobin concentration of more than 5 g/dl. All observed bleeding complications had to be recorded in the patient chart. Results 
Patients
In the 38 patients enrolled, treatment began 2.9 ± 1.1 hours after the onset of symptoms. The mean 
In one patient, a percutaneous transluminal coronary angioplasty (PTCA) procedure was performed at 45 minutes because the clinical situation became unstable, and the infarct vessel was still occluded. In one patient, the infarct artery could not be determined unequivocally, the right coronary artery was completely occluded but well collateralized and could not be reopened by PTCA (presumably an old occlusion). The circumflex artery showed a high-grade stenosis with TIMI grade III blood flow at 60 minutes, however, electrocardiographic changes persisted (judged as left circumflex artery in Table 1 and as "not assessable" for Figure 1 ).
Specificity of Treatment
Intravenous thrombolytic therapy with the combination of rt-PA and scuPA induced little systemic activation of the fibrinolytic system as summarized in Figure 2 . At 60 and 120 minutes, the fibrinogen level had declined to 82.8±+-24.3% (n=34) and 91.2+17.4% (n=32) of pretreatment values, respectively. The initial decline probably also reflects dilution by the various infusions and possibly some in vitro degradation. Notably, at 60 minutes, only four of 34 patients (11.8%) had a transient fibrinogen reduction to less than 100 mg/dl, among them was one patient (2.9%) with less than 50 mg/dl. At 120 minutes, the fibrinogen level was well above 100 mg/dl in all patients. The mean plasminogen concentration in the patients was 88.2+18.2% (n=34) of a normal reference plasma at the beginning of therapy. At 60 minutes, plasminogen levels had declined to 66.3+15.2% (n=31) of pretreatment levels, and they remained stable at 120 minutes at 65.3+13.4 (n=31) of the initial plasminogen level. a2-Antiplasmin, the most sensitive measure of plasmin generation, was 98.8+16.4% (n=33) of a normal reference plasma at the outset of therapy. At 60 and 120 minutes, a2-antiplasmin levels had declined to 30.7+22.8% (n=33) and 32.2+21.2% (n=31) of pretreatment values, respectively. This indicates that, although some free plasmin was generated, the neutralizing capacity of the antiplasmin system was not exhausted. Therefore, the total dose of plasminogen activators used seems to be just below the threshold of specificity, as was estimated at the start of this trial.
Side Effects
No bleeding complications necessitating transfusion occurred. There was no report of overt bleeding or excessive hematoma at the puncture site. Hemoglobin concentration 1 consumption of plasminogen and with significant degradation of fibrinogen. Although these changes are greater with streptokinase, APSAC, and urokinase, monotherapy with rt-PA and scuPA are also almost nonspecific at the high doses required for efficacy. In a recent randomized trial, 80 mg recombinant unglycosylated scuPA produced patency in 71.2% of patients, at 90 minutes, associated with extensive fibrinogenolysis (mean of 79 mg/dl at 60 minutes). 18 It is important to realize that, calculated from the specific activities of the two agents, 80 mg recombinant scuPA (specific activity, 175,000 lU)32 corresponds to approximately 100 mg glycosylated scuPA (specific activity, 130,000 IU).17'3334 Thus, only about one half of the standard amount of scuPA was used in this trial in combination with rt-PA. As a consequence, the observed changes in plasma parameters were mild and comparable with those observed using similar amounts of glycosylated scuPA alone '7,33 Coronary thrombolysis by an adequate combination of rt-PA and scuPA was found to be at least as effective, more efficient, and more specific than that reported for standard monotherapy with either activator. The frequency of reocclusion in combination with PTCA remains high and requires an alternative solution. More extensive trials are required to determine if combinations of tPA and scuPA should be substituted for monotherapy in the treatment of acute myocardial infarction and to establish the optimal dosage combination of the activators.
